Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02004678
Recruitment Status : Completed
First Posted : December 9, 2013
Last Update Posted : December 24, 2018
Sponsor:
Information provided by (Responsible Party):
Daiichi Sankyo, Inc.

Tracking Information
First Submitted Date  ICMJE October 25, 2013
First Posted Date  ICMJE December 9, 2013
Last Update Posted Date December 24, 2018
Study Start Date  ICMJE September 2013
Actual Primary Completion Date September 2013   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 4, 2013)
  • area under curve (AUC) [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus.
  • maximum plasma concentration (Cmax) [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus.
  • terminal elimination half-life (t1/2) [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus.
  • time to reach maximum plasma concentration (Tmax) [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02004678 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: December 4, 2013)
  • measure the effects on Insulin and C-peptide Levels [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the effects of single oral dose of DS-1150b on insulin and C-peptide levels in subjects with Type 2 Diabetes Mellitus.
  • number of patients experiencing adverse events [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the safety and tolerability of single oral dose of DS-1150b in subjects with Type 2 diabetes mellitus.
  • measure the effects on glucagon Levels [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the effects of single oral dose of DS-1150b on glucagon levels in subjects with Type 2 Diabetes Mellitus.
  • number of patients experiencing laboratory adverse events [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the safety and tolerability of single oral dose of DS-1150b in subjects with Type 2 diabetes mellitus.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus
Official Title  ICMJE Phase I, Single-Blind, Placebo-Controlled, Randomized, Two-Part, Sequential, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus
Brief Summary DS-1150b is being developed by Daiichi Sankyo for the treatment of Type 2 Diabetes Mellitus. This is a Phase I, single-blind (subjects and principal investigator blinded, Sponsor unblinded), placebo‑controlled, randomized, 2‑part, sequential, single ascending dose, single center study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral dose of DS‑1150b in healthy subjects and subjects with Type 2 Diabetes Mellitus.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Type 2 Diabetes Mellitus
Intervention  ICMJE
  • Drug: DS-1150b
  • Other: Placebo
Study Arms  ICMJE
  • Cohort 1, 7.5 mg DS-1150b

    Dosing will occur over two periods. Subjects will receive either

    • a dose of placebo in Period 1 followed by a single dose of 7.5 mg DS-1150b in Period 2; or
    • a single dose of 7.5 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2.
    Interventions:
    • Drug: DS-1150b
    • Other: Placebo
  • Cohort 2, 15 mg DS-1150b

    Dosing will occur over two periods. Subjects will receive either

    • a dose of placebo in Period 1 followed by a single dose of 15 mg DS-1150b in Period 2; or
    • a single dose of 15 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2.
    Interventions:
    • Drug: DS-1150b
    • Other: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 4, 2013)
40
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE October 2013
Actual Primary Completion Date September 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

All Subjects:

  • All women must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1. Women must be of non-childbearing potential, either:

    • Surgically sterile (ie, bilateral tubal ligation or removal of both ovaries and/or uterus at least 6 months prior to dose administration).
    • <60 years of age and naturally postmenopausal (spontaneous cessation of menses) for at least 24 consecutive months prior to dose administration, with a follicle stimulating hormone (FSH) level at screening of

      ≥40 mIU/mL.

    • >60 years of age and naturally postmenopausal (spontaneous cessation of menses) for at least 24 consecutive months prior to dose administration.
  • Male subjects have to agree to contraception (condom with spermicide) in addition to having their female partner (if of child-bearing potential) use another form of contraception (eg, an intrauterine device, diaphragm with spermicide, oral until 12 weeks following the last dose administration. In addition, the male subjects must not donate sperm after the study for a period of 12 weeks.
  • Subjects must give written informed consent to participate in the study prior to screening.
  • Subjects must be in good health as determined by screening medical history, physical examination findings, vital signs measurement, ECGs, serum chemistry, hematology, virology (ie, HIV, HBV, and HCV at screening only), and urinalysis performed at screening and on Day -1.
  • Subjects must agree to abstain from grapefruit/grapefruit juice and Seville oranges from 10 days before the first dose and throughout the study.
  • All subjects must have a negative fecal occult blood test.

Part B (Type 2 Diabetes Mellitus):

  • Men and women who are not of childbearing potential, 18 years to 60 years of age, inclusive.
  • A BMI of 25 kg/m2 to 38 kg/m2, inclusive.
  • Diagnosis of Type 2 DM for a minimum of 3 months prior to first dose.
  • Subjects should be either:

    • On metformin alone with a hemoglobin A1c (HBA1c) value between 7% to 9.5%, inclusive.
    • Treatment naïve or treatment free from any antidiabetic treatment for at least 3 months prior to screening with a HBA1c value between 7% to 10%, inclusive.
  • Subjects with fasting plasma glucose ≥100 mg/dL and ≤250 mg/dL, for screening and on Day -1.

Exclusion Criteria:

All Subjects:

  • History of gastrointestinal ulcer or erosion, or rhabdomyolysis within 6 months of dose administration.
  • Subjects with laboratory results outside the normal range, if considered clinically significant by the Investigator.
  • Subjects with serum K above the ULN of the clinical laboratory's reference range at screening and on Day -1.
  • Subjects with CPK above the ULN at screening and on Day -1.
  • Subjects with lactate above the ULN at screening and on Day -1.
  • Subjects with QTcF interval duration >450 msec, obtained as an average from the 3 ECG recorder's measurements on the triplicate screening ECGs (3 ECGs in close succession at least 1 min apart) taken after at least 10 minutes of quiet rest in supine position.
  • Subjects with abnormal waveform morphology on any of the ECGs at the screening and on Day -1 that would preclude accurate measurement of the QT interval duration.
  • History of any serious disorder, including cardiovascular, hematologic, pulmonary, hepatic, renal, gastrointestinal, skeletal, connective tissue disease, uncontrolled endocrine/metabolic other than subjects with Type 2 DM in Part B, oncologic (within the last 5 years), neurologic, and psychiatric diseases, or any disorder that may prevent the successful completion of the study.
  • Subjects who have had physical trauma, surgery or a significant illness within 4 weeks prior to the first dose.
  • Donated or lost >500 mL of blood or plasma within 3 months prior to the first dose on Day 1.
  • Participated in a clinical study involving administration of an investigational drug (new chemical entity), or a marked drug within the 30 days prior to administration of the first dose.

Part B (Type 2 Diabetes Mellitus)

  • History of Type 1 diabetes and/or history of acute or chronic metabolic acidosis, including diabetic ketoacidosis.
  • History of severe microvascular or macrovascular complications of Type 2 DM, including proliferative retinopathy, macroalbuminuria, peripheral neuropathy, ischemic heart disease, stroke, and peripheral vascular disease.
  • History of diabetic neuropathy.
  • Need for any concomitant medication that is moderate or strong CYP inhibitors including CYP3A4, CYP2D6, CYP2C9, and CYP2C19, or P-gp inhibitor. Need for other antidiabetic drugs except for metformin. Other common concomitant medications in diabetic patients may be allowed (eg, aspirin and thyroid hormones) upon agreement between the Sponsor and the PI.
  • Subjects with liver function of ALT and AST above 1.25 × ULN, or total bilirubin above ULN at screening and on Day -1.
  • Moderate or severe renal dysfunction, defined as eGFR (using MDRD equation) <60 mL/min.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02004678
Other Study ID Numbers  ICMJE DS1150-A-U101
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Supporting Materials: Informed Consent Form (ICF)
Supporting Materials: Clinical Study Report (CSR)
Supporting Materials: Analytic Code
Time Frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
URL: https://vivli.org/ourmember/daiichi-sankyo/
Responsible Party Daiichi Sankyo, Inc.
Study Sponsor  ICMJE Daiichi Sankyo, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Daiichi Sankyo, Inc.
Verification Date December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP